ANNOVIS BIO INC. COMMON STOCK
3.0800
06-February-25 16:15:00
15 minutes delayed
Stocks
-0.0600
-1.91%
Today's range
2.9950 - 3.1600
ISIN
N/A
Source
NYSE
-
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
27 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
26 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
25 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
-
18 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Announces New Publication in a Peer-Reviewed Journal
21 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
13 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
09 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
06 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
29 Apr 2024 10:10:00 By Nasdaq GlobeNewswire
-
02 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
-
01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire
-
20 Mar 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
-
14 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
-
30 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
24 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio to Participate in the 139th Yale CEO Summit
11 Dec 2023 13:00:00 By Nasdaq GlobeNewswire